236 related articles for article (PubMed ID: 20603272)
1. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects.
Miura S; Karnik SS; Saku K
J Renin Angiotensin Aldosterone Syst; 2011 Mar; 12(1):1-7. PubMed ID: 20603272
[TBL] [Abstract][Full Text] [Related]
2. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers.
Imaizumi S; Miura S; Yahiro E; Uehara Y; Komuro I; Saku K
Curr Pharm Des; 2013; 19(17):3002-8. PubMed ID: 23176212
[TBL] [Abstract][Full Text] [Related]
3. Do all angiotensin II type 1 receptor blockers have the same beneficial effects?
Miura S; Saku K
Br J Pharmacol; 2007 Aug; 151(7):912-3. PubMed ID: 17572701
[TBL] [Abstract][Full Text] [Related]
4. Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor.
Takezako T; Unal H; Karnik SS; Node K
Mol Pharmacol; 2015 Sep; 88(3):488-501. PubMed ID: 26121982
[TBL] [Abstract][Full Text] [Related]
5. Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.
Takezako T; Unal H; Karnik SS; Node K
Pharmacol Res; 2017 Sep; 123():40-50. PubMed ID: 28648738
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin type 1 receptor resistance to blockade in the opossum proximal tubule cell due to variations in the binding pocket.
Nistala R; Andresen BT; Pulakat L; Meuth A; Sinak C; Mandavia C; Thekkumkara T; Speth RC; Whaley-Connell A; Sowers JR
Am J Physiol Renal Physiol; 2013 Apr; 304(8):F1105-13. PubMed ID: 23389452
[TBL] [Abstract][Full Text] [Related]
7. Divergent Spatiotemporal Interaction of Angiotensin Receptor Blocking Drugs with Angiotensin Type 1 Receptor.
Singh KD; Unal H; Desnoyer R; Karnik SS
J Chem Inf Model; 2018 Jan; 58(1):182-193. PubMed ID: 29195045
[TBL] [Abstract][Full Text] [Related]
8. The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives.
Agelis G; Resvani A; Durdagi S; Spyridaki K; Tůmová T; Slaninová J; Giannopoulos P; Vlahakos D; Liapakis G; Mavromoustakos T; Matsoukas J
Eur J Med Chem; 2012 Sep; 55():358-74. PubMed ID: 22889560
[TBL] [Abstract][Full Text] [Related]
9. Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers-Relevance to COVID-19.
Moore GJ; Pires JM; Kelaidonis K; Gadanec LK; Zulli A; Apostolopoulos V; Matsoukas JM
Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356603
[TBL] [Abstract][Full Text] [Related]
10. AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.
Harada N; Shimozawa N; Okajima K
Transl Res; 2009 Sep; 154(3):142-52. PubMed ID: 19665690
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.
Le MT; Pugsley MK; Vauquelin G; Van Liefde I
Br J Pharmacol; 2007 Aug; 151(7):952-62. PubMed ID: 17572702
[TBL] [Abstract][Full Text] [Related]
12. Reassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockers.
Miura S; Nakao N; Hanzawa H; Matsuo Y; Saku K; Karnik SS
PLoS One; 2013; 8(11):e79914. PubMed ID: 24260317
[TBL] [Abstract][Full Text] [Related]
13. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.
Iwanaga T; Sato M; Maeda T; Ogihara T; Tamai I
J Pharmacol Exp Ther; 2007 Jan; 320(1):211-7. PubMed ID: 17043154
[TBL] [Abstract][Full Text] [Related]
14. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.
Wang X; Ye Y; Gong H; Wu J; Yuan J; Wang S; Yin P; Ding Z; Kang L; Jiang Q; Zhang W; Li Y; Ge J; Zou Y
J Mol Cell Cardiol; 2016 Aug; 97():180-90. PubMed ID: 27210827
[TBL] [Abstract][Full Text] [Related]
15. Engagement of renin-angiotensin system in prostate cancer.
Uemura H; Hoshino K; Kubota Y
Curr Cancer Drug Targets; 2011 May; 11(4):442-50. PubMed ID: 21395553
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II cyclic analogs as tools to investigate AT
St-Pierre D; Cabana J; Holleran BJ; Besserer-Offroy É; Escher E; Guillemette G; Lavigne P; Leduc R
Biochem Pharmacol; 2018 Aug; 154():104-117. PubMed ID: 29684376
[TBL] [Abstract][Full Text] [Related]
17. Unique "delta lock" structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor.
Ohno K; Amano Y; Kakuta H; Niimi T; Takakura S; Orita M; Miyata K; Sakashita H; Takeuchi M; Komuro I; Higaki J; Horiuchi M; Kim-Mitsuyama S; Mori Y; Morishita R; Yamagishi S
Biochem Biophys Res Commun; 2011 Jan; 404(1):434-7. PubMed ID: 21130741
[TBL] [Abstract][Full Text] [Related]
18. Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor.
Balakumar P; Jagadeesh G
J Mol Endocrinol; 2014 Oct; 53(2):R71-92. PubMed ID: 25013233
[TBL] [Abstract][Full Text] [Related]
19. Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors.
Mogi M; Iwai M; Horiuchi M
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2532-9. PubMed ID: 17717300
[TBL] [Abstract][Full Text] [Related]
20. Valsartan ameliorates the constitutive adipokine expression pattern in mature adipocytes: a role for inverse agonism of the angiotensin II type 1 receptor in obesity.
Hasan AU; Ohmori K; Hashimoto T; Kamitori K; Yamaguchi F; Ishihara Y; Ishihara N; Noma T; Tokuda M; Kohno M
Hypertens Res; 2014 Jul; 37(7):621-8. PubMed ID: 24599011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
